Paradigm Capital Management Inc. NY Grows Position in Enovis Corporation $ENOV

Paradigm Capital Management Inc. NY increased its holdings in Enovis Corporation (NYSE:ENOV) by 70.2% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 1,776,715 shares of the company’s stock after buying an additional 732,917 shares during the quarter. Enovis comprises approximately 1.5% of Paradigm Capital Management Inc. NY’s portfolio, making the stock its 16th biggest position. Paradigm Capital Management Inc. NY’s holdings in Enovis were worth $40,420,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ENOV. California State Teachers Retirement System lifted its stake in Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after acquiring an additional 621 shares during the period. MGO One Seven LLC lifted its holdings in shares of Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after buying an additional 650 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. Empowered Funds LLC boosted its stake in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. Finally, Inscription Capital LLC boosted its stake in shares of Enovis by 9.4% in the 4th quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock worth $316,000 after buying an additional 1,016 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Evercore set a $32.00 target price on Enovis in a report on Monday, July 6th. BMO Capital Markets started coverage on Enovis in a research note on Wednesday, July 8th. They set an “outperform” rating and a $29.00 price target for the company. Zacks Research lowered shares of Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 30th. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. Finally, Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.71.

Enovis Price Performance

NYSE ENOV opened at $27.05 on Friday. The business’s fifty day moving average is $23.65 and its 200 day moving average is $23.78. Enovis Corporation has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a market capitalization of $1.56 billion, a PE ratio of -1.36 and a beta of 1.39.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts predict that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.